Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL

NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, reported the Phase I clinical entry and the dosing of patients with the bispecific JNJ-75348780 in a Phase I study (https://clinicaltrials.gov/ct2/show/NCT04540796), which is sponsored by Janssen Research & Development, LLC (Janssen). The Phase I dose escalation study will evaluate patients with B-cell lymphoid malignancies, including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Participants will receive JNJ-75348780 by intravenous (IV) or subcutaneous (SC) administration.

Read more

Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer

NEWARK, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific T-cell engaging antibody for the treatment of metastatic castrate resistant prostate cancer (mCRPC) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on January 23, 2021.

Read more

Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma

NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported initial results of a Phase I trial (https://clinicaltrials.gov/ct2/show/NCT03933735) evaluating TNB-383B in Relapsed Refractory Multiple Myeloma (R/R MM) on December 5 at the 62nd American Society of Hematology Annual Conference. TNB-383B is a fully human bispecific antibody that targets BCMA on the surface of multiple myeloma (MM) cells and CD3 on the surface of T cells in order to trigger lysis of MM cells in MM patients. The ongoing open-label multi-center trial is designed to assess the safety, pharmacokinetics and preliminary efficacy of TNB-383B administered intravenously once every 21 days.

Read more

Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies

NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to develop novel CAR T therapies. Poseida will apply licensed UniDab binders, which possess significant advantages over traditional single chain variable antibody fragment (scFv) binders, to develop its next generation CAR-T therapies. Targets were not disclosed.

Read more

Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology

NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) — Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced the presentation of interim clinical data from its Phase 1 trial evaluating TNB-383B in relapsed/refractory multiple myeloma (R/R MM) at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually Dec. 5-8, 2020. TNB-383B is a fully human bispecific antibody that targets BCMA on the surface of multiple myeloma (MM) cells and CD3 on the surface of T cells in order to trigger lysis of MM cells in R/R MM patients. The open-label multi-center trial is designed to assess the safety, pharmacokinetics and preliminary efficacy of TNB-383B administered intravenously once every 21 days.

Read more

TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals

NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication (https://www.nature.com/articles/s42255-020-00298-z) of a proof of concept study by the Chini Laboratory (Mayo Clinic’s campus in Rochester, Minnesota) describing the rejuvenation of energy metabolism in aged mice undergoing therapy with Teneobio’s CD38 blocker.

Read more

Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio

NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.

Read more

Teneobio Announces US FDA Clearance of Investigational New Drug Application for TNB-486 and the Initiation of Phase I Clinical Studies in Patients with B-cell Malignancies

NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoTwo, Inc. announced today that their investigational new drug application (IND) for TNB-486, a bispecific T-cell engaging antibody for the treatment of B-Cell Non-Hodgkin’s lymphoma (B-NHL) was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on September 30, 2020.

Read more

Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics

NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs®) for Intellia’s next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs® against targets which can be used in engineered cell therapies for various life-threatening diseases. Intellia will have the option to exclusively license the novel antibodies for global development and commercialization.

Read more

Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

— Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies —

April 02, 2020 08:30 AM Eastern Daylight Time

SANTA MONICA, Calif. & NEWARK, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA).

Read more